190 related articles for article (PubMed ID: 28825423)
21. α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.
Terry AV; Callahan PM
Neuropharmacology; 2020 Jun; 170():108053. PubMed ID: 32188568
[TBL] [Abstract][Full Text] [Related]
22. Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.
Smith RC; Amiaz R; Si TM; Maayan L; Jin H; Boules S; Sershen H; Li C; Ren J; Liu Y; Youseff M; Lajtha A; Guidotti A; Weiser M; Davis JM
PLoS One; 2016; 11(1):e0143490. PubMed ID: 26730716
[TBL] [Abstract][Full Text] [Related]
23. Initial Cross-Over Test of A Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers With Or Without Schizophrenia.
Perkins KA; Roy Chengappa KN; Karelitz JL; Boldry MC; Michael V; Herb T; Gannon J; Brar J; Ford L; Rassnick S; Brunzell DH
Neuropsychopharmacology; 2018 May; 43(6):1334-1342. PubMed ID: 29185480
[TBL] [Abstract][Full Text] [Related]
24. Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia.
McLean SL; Grayson B; Idris NF; Lesage AS; Pemberton DJ; Mackie C; Neill JC
Eur Neuropsychopharmacol; 2011 Apr; 21(4):333-43. PubMed ID: 20630711
[TBL] [Abstract][Full Text] [Related]
25. Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats.
Jones KM; McDonald IM; Bourin C; Olson RE; Bristow LJ; Easton A
Psychopharmacology (Berl); 2014 Feb; 231(4):673-83. PubMed ID: 24057763
[TBL] [Abstract][Full Text] [Related]
26. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
Haig G; Wang D; Othman AA; Zhao J
Neuropsychopharmacology; 2016 Nov; 41(12):2893-2902. PubMed ID: 27319970
[TBL] [Abstract][Full Text] [Related]
27. Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.
Potasiewicz A; Nikiforuk A; Hołuj M; Popik P
J Psychopharmacol; 2017 Feb; 31(2):260-271. PubMed ID: 28168926
[TBL] [Abstract][Full Text] [Related]
28. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.
Buccafusco JJ; Terry AV
Biochem Pharmacol; 2009 Oct; 78(7):852-62. PubMed ID: 19577545
[TBL] [Abstract][Full Text] [Related]
29. Brain PET Imaging of α7-nAChR with [18F]ASEM: Reproducibility, Occupancy, Receptor Density, and Changes in Schizophrenia.
Wong DF; Kuwabara H; Horti AG; Roberts JM; Nandi A; Cascella N; Brasic J; Weerts EM; Kitzmiller K; Phan JA; Gapasin L; Sawa A; Valentine H; Wand G; Mishra C; George N; McDonald M; Lesniak W; Holt DP; Azad BB; Dannals RF; Kem W; Freedman R; Gjedde A
Int J Neuropsychopharmacol; 2018 Jul; 21(7):656-667. PubMed ID: 29522184
[TBL] [Abstract][Full Text] [Related]
30. Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.
Olincy A; Freedman R
Handb Exp Pharmacol; 2012; (213):211-32. PubMed ID: 23027417
[TBL] [Abstract][Full Text] [Related]
31. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
[TBL] [Abstract][Full Text] [Related]
32. DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats.
O'Neill HC; Rieger K; Kem WR; Stevens KE
Psychopharmacology (Berl); 2003 Sep; 169(3-4):332-9. PubMed ID: 12759805
[TBL] [Abstract][Full Text] [Related]
33. Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice.
Stevens KE; Cornejo B; Adams CE; Zheng L; Yonchek J; Hoffman KL; Christians U; Kem WR
Brain Res; 2010 Sep; 1352():140-6. PubMed ID: 20599427
[TBL] [Abstract][Full Text] [Related]
34. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner.
Meyer EM; Tay ET; Papke RL; Meyers C; Huang GL; de Fiebre CM
Brain Res; 1997 Sep; 768(1-2):49-56. PubMed ID: 9369300
[TBL] [Abstract][Full Text] [Related]
35. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.
Martin LF; Kem WR; Freedman R
Psychopharmacology (Berl); 2004 Jun; 174(1):54-64. PubMed ID: 15205879
[TBL] [Abstract][Full Text] [Related]
36. Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.
Marquis KL; Comery TA; Jow F; Navarra RL; Grauer SM; Pulicicchio C; Kelley C; Brennan JA; Roncarati R; Scali C; Haydar S; Ghiron C; Terstappen GC; Dunlop J
Psychopharmacology (Berl); 2011 Dec; 218(4):635-47. PubMed ID: 21643676
[TBL] [Abstract][Full Text] [Related]
37. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
Martin LF; Freedman R
Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
[TBL] [Abstract][Full Text] [Related]
38. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial.
Barch DM; Marder SR; Harms MP; Jarskog LF; Buchanan RW; Cronenwett W; Chen LS; Weiss M; Maguire RP; Pezous N; Feuerbach D; Lopez-Lopez C; Johns DR; Behrje RB; Gomez-Mancilla B
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():66-75. PubMed ID: 27371157
[TBL] [Abstract][Full Text] [Related]
39. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.
Winterer G; Gallinat J; Brinkmeyer J; Musso F; Kornhuber J; Thuerauf N; Rujescu D; Favis R; Sun Y; Franc MA; Ouwerkerk-Mahadevan S; Janssens L; Timmers M; Streffer JR
Neuropharmacology; 2013 Jan; 64():197-204. PubMed ID: 22766391
[TBL] [Abstract][Full Text] [Related]
40. The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease.
Qi XL; Nordberg A; Xiu J; Guan ZZ
Neurochem Int; 2007; 51(6-7):377-83. PubMed ID: 17493709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
